Fibrogen,

We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers.